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  2 
Introduction 3 
While it is generally recognised that the treatment of both Borderline and Dissocial 4 
Personality Disorder (BPD and DPD) is predominantly psychological, targeted drug 5 
treatment of individual symptoms may be helpful for some patients (Cloninger, 1998). Over 6 
recent years, there have been several randomised controlled trials evaluating the use of 7 
psychotropic medication in personality disorder, but none to date with clozapine (Goldberg et 8 
al. 1986, Bogenschutz and George 2004). These trials of drug treatment are in comparison at 9 
least as good as those of other interventions, although the treatments have seldom persisted 10 
beyond a few weeks (Tyrer and Bateman 2004).  11 
 12 
In people with Intellectual Disability (ID) the diagnosis of BPD or DPD is carefully made 13 
due to the possibility of diagnostic overshadowing between personality characteristics, 14 
intellectual ability, autism, mental illness and/or challenging behaviour (Royal College of 15 
Psychiatrists, 2001). The diagnosis of personality disorders in people with ID can sometimes 16 
be contentious and in routine clinical practice is limited to those with mild and borderline ID . 17 
In the UK, the rate of personality disorders is around 7% for patients in contact with 18 
community ID teams and 50-60% within forensic ID services. Personality disorders 19 
diagnosed in both these settings tend to be those in the borderline and dissocial categories 20 
(Alexander et al., 2007; Alexander and Cooray 2003; Naik et al., 2002).  21 
  22 
The evidence for drug treatment of BPD and DPD in ID is limited to case reports or small 23 
case series. Day (1988) reported a case series of twenty people with ID and personality 24 
disorder with history of offending behaviour and showed that 70% were prescribed 25 
psychotropic medication.(Day, 1988)  Naik et al. (2002) noted that in their sample of adults 26 
with ID and personality disorder, a third had co-morbid mental illnesses but 90% were 27 
receiving psychotropic medication (Naik et al., 2002). Mavromatis (2000) described a 28 
significant clinical improvement with the use of Olanzapine in two patients and a Fluoxetine 29 
and Semisodium Valproate combination in a patient with ID and BPD (Mavromatis, 2000). 30 
Alexander et al. (2007) explored the target symptoms for pharmacological treatment and 31 
discussed the framework of five main symptom domains within personality disorders in ID. 32 
Behaviour dyscontrol was present in 93%, affective dysregulation in 77%, self-injurious 33 
behaviour in 52%, cognitive perceptual symptoms in 47% and anxiety in 33%. 82% of 34 
subjects had features in ≥2 domains (Alexander et al., 2007). 35 
  36 
With regard to clozapine, there is a growing evidence base in support of its use in the context 37 
of BPD and DPD. Thalayasingam et al. (2004) described a case series of 24 patients with an 38 
ID and mental health difficulties who were treated with clozapine, of which three had a 39 
personality disorder and a favourable response to  treatment. Of the three, one did have a co-40 
morbid schizophrenia and another a bipolar disorder (Thalayasingam et al., 2004). Biswas et 41 
al. (2006) described a significant and sustained improvement in both mood and impulsivity 42 
over a period of four years in a person with ID & BPD receiving treatment with clozapine 43 
(Biswas et al., 2006). 44 
  45 
In this case series we have attempted to identify long-term outcome of treatment, of 5 patients 46 
with ID and personality disorders at the end of a 36 months of treatment with clozapine by:  47 
1.     Comparing the severity of symptom clusters (Tables 1 & 2). The 48 
symptoms have been rated on a 4 point Likert scale of severity.   49 
2.     Comparing the number of admissions to the inpatient psychiatric 50 
unit before and after starting clozapine. 51 
 52 
Case studies  53 
 54 
Case A 55 
A is a 36-year-old female with mild ID (55<IQ<70), BPD, epilepsy and depressive disorder. 56 
Her mother had a history of mental health problems. There was no history of ID in the 57 
family. She is the youngest of five siblings. She was born after prolonged labour, suffering 58 
from seizures a few days after birth. She had delayed development of speech, language and 59 
social skills. She also suffered from abuse, neglect and parental separation during her 60 
childhood. She lived at home with her mother until the age of seventeen, but due to severe 61 
behavioural problems was seen by a child psychiatrist and later placed in residential care, 62 
where she presented with physical and verbal aggression towards others, noisy behaviour, 63 
damage to property, threats of self-harm, constant reassurance seeking and self-injurious 64 
behaviour including severe head banging, frequent overdoses and cutting herself.  65 
  66 
Over a four year period, she was admitted to the inpatient psychiatric unit on 5 occasions, 67 
some of them under the Mental Health Act (MHA) 1983. During this time she was also 68 
placed in different residential homes, but these placements broke down due to her severe 69 
challenging behaviour. She was admitted once more several years later due to challenging 70 
behaviour in the form of repetitive demands and impulsively aggressive and self- injurious 71 
behaviour, where she remained an inpatient for one year. During this time clozapine was 72 
initiated after unsuccessful treatment with different antipsychotic medications over years. She 73 
then gradually started to show a reduction in her behaviours. Additionally, she started 74 
engaging in behavioural treatment programmes, went for visits in the community without 75 
incidents and consented to take her psychotropic medication. During admission, psychosocial 76 
support from the various members of the Multi-Disciplinary Team (MDT) continued as 77 
before. She was eventually discharged into a supported living scheme under a Care 78 
Programme Approach (CPA), where she has remained to date with no further admissions or 79 
serious incidents.  80 
  81 
Case B 82 
B is a 37-year-old female with mild ID, BPD, dissocial traits and depressive disorder with 83 
psychotic symptoms. Her brother has ID and schizophrenia, her mother suffers from 84 
depressive disorder and her biological father has a history of schizophrenia. At birth, she 85 
suffered from breathing difficulties and was neglected by her mother due to post-natal 86 
depression. She had delayed milestones and only started to walk at the age of two years and 87 
uttered her first words at the age of three. She attended a special school till the age of sixteen, 88 
as she needed help with reading and writing. During her childhood and adolescence her 89 
mother had severe mental health problems and was in hospital for a prolonged period; it was 90 
during this time that her father repeatedly emotionally and sexually abused her. She was later 91 
taken into foster care. 92 
 93 
By the time that she came into contact with mental health services, she  presented with 94 
features of depression and psychotic symptoms (including nihilistic delusions). She was 95 
admitted to an in-patient ward and detained under the MHA 1983. During her initial stay in 96 
hospital she was initiated on olanzapine, with which she was non-compliant. She 97 
continuously threatened to blow up the drug trolley and made statements of wanting to take 98 
her life. She tried to strangle herself using a stereo cable and undergarments, cut her wrists 99 
using pieces of broken CDs, head-butted windows and once put her foot under the wheel of a 100 
car, causing soft tissue injury. She had also disclosed that she could feel a metal object being 101 
inserted into her vagina by an old lady. She was then initiated on both zuclopenthixol 102 
decanoate (depot antipsychotic) due to her non-compliance and paroxetine (antidepressant). 103 
Towards the end of her stay in hospital, she became compliant with medications and was 104 
reinstated on olanzapine. After she was discharged to live with her mother and stepfather, she 105 
developed a relationship with a man and moved to her own flat, but this relationship lasted 106 
for only 3 weeks and it subsequently became clear that she was not able to cope on her own. 107 
She started drinking heavily and made threats to self-harm. 108 
 109 
She was admitted 8 times over the next few years, some of the admissions under the MHA 110 
(1983) and was tried on various psychotropic medications including olanzapine, 111 
zuclopenthixol decanoate, chlorpromazine, amisulpiride and paroxetine with no long term 112 
benefits. She also received intensive support from the psychology team and nursing staff on 113 
the ward. 114 
 115 
In her last hospital stay she was initiated on clozapine, upon which she responded well.  She 116 
was eventually discharged with supervised community treatment aftercare provisions. She is 117 
currently settled in her mental state and is functioning well with support in the community.  118 
  119 
  120 
Case C  121 
C is a 32-year-old female with mild ID, BPD and DPD. She has no family history of mental 122 
illness or ID. She was born at full term without any reported perinatal complications. She had 123 
delayed developmental milestones and attended a special school. She also suffered from 124 
several traumatic childhood experiences including childhood sexual abuse, domestic violence 125 
and parental divorce. During her childhood she displayed several behavioural problems, as a 126 
result of which at the age of 11, she was admitted to a residential school for children with 127 
learning difficulties and behavioural problems. She was seen by a psychiatrist and was 128 
prescribed antidepressants and also had some counselling sessions. 129 
 130 
She came into contact with ID psychiatric services during early adulthood, mainly in times of 131 
crisis when she would present frequently with risk-taking/ dangerous behaviour including 132 
absconding from home, threatening to jump off buildings, property damage, self-cutting, 133 
making emergency telephone calls and assaulting police officers. She also reported feelings 134 
of abandonment, and hopelessness. There were no sustained periods of low mood or 135 
psychotic symptoms.  136 
 137 
It was difficult for the psychiatric team to engage her in any meaningful therapeutic work due 138 
to her impulsivity and presenting in crises. She was tried on a number of psychotropic 139 
medications including mood stabilisers (carbamazepine and lithium), antidepressants 140 
(fluoxetine, trazodone, sertraline, paroxetine and fluvoxamine), anxiolytics (diazepam, 141 
lorazepam and propranolol) and antipsychotics (zuclopenthixol dihydrochloride, flupentixol 142 
decanoate, thioridazine, risperidone, olanzapine, sulpiride, amisulpiride, droperidol and 143 
haloperidol) over years with no long-term benefits.  144 
 145 
Despite a high level of support from the MDT in the community, she required frequent 146 
admissions to the inpatient unit. These admissions were precipitated by self-harm or 147 
aggressive behaviour, and persisted during the admission on the ward in the form of 148 
aggression, breaking objects, absconding and self-harm. 149 
 150 
During her last admission, a trial of clozapine was considered in view of her high levels of 151 
impulsivity and arousal and lack of response to numerous previous medications and non-152 
pharmacological approaches. By the end of the sixth week of treatment she was well enough 153 
to go to several periods of home leave following which she was subsequently discharged to 154 
live in the community. There was a significant reduction in her impulsivity and emotional 155 
lability following initiation of clozapine. She was able to recognise early warning signs, 156 
which could lead to a crisis and could start engaging with the psychiatric team. Her mood has 157 
remained euthymic and she has been stable in the community for the past four and a half 158 
years without any need for further admission. 159 
  160 
Case D 161 
D is a 28 year old female with a history of mild ID, BPD and schizophrenia. She was born 162 
with her umbilical cord around her neck; however there were no other antenatal or perinatal 163 
complications. She showed delayed developmental milestones and was placed on a statement 164 
of special educational needs at the age of 5. There was no history of ID in her family. D’s 165 
parents separated when she was a teenager.  166 
 167 
She first became known to the adult ID team at the age of 19, when she was referred with 168 
suspected depression by her GP.  Following a series of life events she was diagnosed with 169 
adjustment disorder with features of depression. However, in the community she was noted to 170 
display challenging behaviours; she attempted to run away from home, expressed paranoid 171 
ideas and complained of hearing voices, for which she was started on olanzapine.  Over the 172 
following 9 years, D was admitted to hospital 4 times, some of which under the Mental 173 
Health Act (1983). During these admissions, she was assessed by several consultant 174 
psychiatrists as well as clinical psychologists, all of whom agreed that in addition to her 175 
treatment resistant psychosis, D showed features of BPD, including impulsiveness, hostility, 176 
uncontained emotions and difficulties with self-identity.  It was the multi-disciplinary team’s 177 
view that these repeated admissions were often prompted by emotional strain at home, which 178 
D was unable to cope with. She made multiple allegations of abuse about members of staff 179 
involved in her care and her family, coupled with becoming verbally abusive, at times violent 180 
to property and threatened suicide.  D also reported auditory and visual hallucinations. 181 
 182 
During her latest admission under the MHA, D was treated with psychological input, as well 183 
as a variety of antidepressants (including paroxetine, citalopram and mirtazapine) in 184 
combination with mood stabilisers and/or antipsychotics (e.g. risperidone, olanzapine, 185 
sodium valproate, amisulpiride and aripiprazole), all with limited clinical impact.  D also 186 
displayed clear psychotic symptomatology (e.g. formal thought disorder, delusions of control, 187 
neologisms and hallucinations in various modalities) independent of the features of BPD, 188 
resulting in a diagnosis of Schizophrenia.   189 
 190 
At the time of writing this article, D has been on clozapine for over 4 years. With the 191 
introduction of clozapine, abusive and aggressive outbursts disappeared and she has shown 192 
much less evidence of emotional volatility since. Although from time to time in reaction to 193 
stressful family and social situations D makes threats of self-harm or report hearing voices, 194 
these are amenable to distraction techniques and engaging her in meaningful activities. She 195 
lives in supported living accommodation with one-to-one support during the daytime, and is 196 
participating in college and structured daily activities.  Over the past 4 years, D has only 197 
needed one informal admission during a community crisis which lasted about 10 days and 198 
was successfully discharged back to her supported living placement again. 199 
Case E 200 
E is a 48 year old married lady with a mild ID and BPD. She suffered sexual and emotional 201 
abuse during childhood and early adulthood. As a result, she presented with maladaptive 202 
behaviours such as aggression, auditory pseudo-hallucinations, self-harm and suicide 203 
attempts in order to deal with stressful situations. She had frequent admissions to the ID 204 
inpatient unit under the MHA over several years. Since she could not be managed in the 205 
community she was transferred to a low secure out of county mental health unit to address 206 
her severe aggressive and self-harming behaviour. After a few years she was transferred to a 207 
rehabilitation unit under Section 3 of the MHA while being on several psychotropic 208 
medications including an antidepressant, a typical antipsychotic and Lorazepam (on a PRN 209 
basis), but continued to be aggressive and self-injurious. Additionally, she would not go out 210 
of the unit to visit the community or participate in activities. A few weeks after her transfer, 211 
she was started on clozapine with her consent and was taken off her typical antipsychotic 212 
medication. She responded well and was successfully discharged to live in a supported living 213 
accommodation in the community within 18 months of starting clozapine. 214 
 215 
 At the time of writing this report, she has been on clozapine for over 4 years while remaining 216 
stable in the community without presenting with any serious aggression, self-harm or suicidal 217 
attempts. She has however had two short term periods of admission in crisis (each less than 218 
two weeks) in the context of bereavement and ideas of self-harm after her young son died.  219 
She lives in supported living with her husband with minimal staff support and remains in 220 
frequent contact with her family as well as regularly engaging in leisure activities.  221 
  222 
 223 
Discussion 224 
In people with ID and personality disorder five symptom domains that have been suggested 225 
for targeting should psychotropic medication be considered are: 226 
1.     Cognitive-perceptual (psychosis-like) symptoms 227 
2.     Symptoms of affective dysregulation 228 
3.     Symptoms of behavioural dyscontrol, impulsivity or aggression 229 
4.     Anxiety symptoms and  230 
5.     Self-injurious behaviour (Bhaumik and Branford, 2005; Alexander et 231 
al., 2007). 232 
 233 
Table 1 illustrates the presentation of any or all of the five symptom clusters and their 234 
severity before starting clozapine in our patients. Table 2 shows the same clusters three years 235 
after continuous treatment of the patients with clozapine. All five cases reported are females, 236 
and indeed BPD tends to be diagnosed more frequently in females than males, though DPD is 237 
more common in males.  238 
 239 
In the general population, most drug treatment studies in adults have been on Cluster B 240 
personality disorders (particularly Borderline and Dissocial) and have shown that low doses 241 
of antipsychotics, Selective Serotonin Reuptake Inhibitors (SSRIs) and mood stabilisers are 242 
useful for irritability, hostility and aggression. It has been suggested that cognitive-perceptual 243 
symptoms should be treated with low dose antipsychotics; affective dysregulation symptoms 244 
with SSRIs, MAO inhibitors and mood stabilisers; and impulse-behavioural dyscontrol 245 
symptoms with SSRIs, MAO inhibitors, lithium, valproate, carbamazepine and clozapine 246 
(Gunderson and Hoffman, 2007). 247 
 248 
In people with ID, Mavromatis (2000) described three case reports illustrating the complexity 249 
of diagnostic assessment in individuals with BPD and ID providing direction in adapting and 250 
tailoring treatment, both behavioural and psychopharmacological, with subjective 251 
improvements reported (Mavromatis, 2000). However, the long term outcome of treatment 252 
was unavailable. In this case series, outcome over a three year follow-up period, 253 
demonstrated sustained improvement. It is likely that while symptom clusters may remain 254 
unchanged and stable over time, nonetheless the severity and intensity reduces markedly with 255 
treatment with clozapine as noted by direct measurements on the Likert scale and by using 256 
proxy variables - hospital re-admissions.  257 
 258 
Natural spontaneous remission is unlikely to occur so dramatically and improvements 259 
sustained over a three year period in all of the above cases. No changes in their 260 
multidisciplinary treatment programme, social circumstances or life-changes could explain 261 
the recovery in each of the cases as all of them were receiving these treatment modalities 262 
before initiating clozapine. A placebo effect is unlikely due to the clear temporal correlation 263 
between initiation of clozapine and treatment response; this same reason making it similarly 264 
unlikely to have occurred to previous psychological, pharmacological or social treatments. 265 
With the notable exception of Case D, there is no evidence to suggest schizophrenia in any of 266 
the cases, although majority of them presented with short lived quasi psychotic 267 
symptoms/pseudo-hallucinatory experiences. The dose of clozapine used in each of the five 268 
cases was much below the 400-800mg/day recommended range for schizophrenia. The 269 
clinical response was noted within 3-6 weeks of initiating the clozapine in all cases. The only 270 
side effects reported by the patients have been a mild day time over-sedation, increased 271 
appetite and weight gain and drooling which has been mainly during sleep. 272 
 273 
In all cases, the decision to initiate clozapine was not taken lightly. Clozapine was only 274 
started if patients were admitted several times under section. Additionally an informed 275 
consent was taken along with a request from a second opinion doctor to authorise the out of 276 
licence use of clozapine. Patients were informed about regular monitoring, registered with 277 
clozapine clinic and remained compliant to regular Full Blood Count and other side effects 278 
monitoring by their community nurses/ ID psychiatrists. In all 5 cases, clozapine replaced 279 
another antipsychotic medication which had been used unsuccessfully to manage severe 280 
aggressive and self-injurious behaviours. In some of the patients, several antipsychotic 281 
medications had been unsuccessfully used over years for the management of life threatening 282 
symptoms. Use of clozapine in all 5 cases resulted in significant improvement in their quality 283 
of life as all of them were successfully taken off Mental Health Act section and discharged 284 
from hospital to live in a supported living accommodation. Additionally, they all started 285 
participating in various social and leisure activities of their choice and college education 286 
while living near to their families. These were not possible prior to treatment with clozapine 287 
in spite of involvement of the multidisciplinary team and using other pharmacological as well 288 
as non-pharmacological approaches. 289 
 290 
Clozapine mainly blocks D1 and D4 receptors and its effects on D2 receptors are relatively less 291 
than traditional antipsychotics. It also blocks 5HT2 receptors, which may be the reason for its 292 
superior efficacy, as it has been postulated that excessive impulsivity reflects central 293 
serotonergic system dysfunction and that clozapine may improve this due to its potent 5HT2 294 
antagonistic activity.    295 
 296 
Clozapine prescription has numerous potential risks. Regular haematological monitoring is 297 
indicated owing to the possibility of developing neutropenia and potentially fatal 298 
agranulocytosis (in 0.01-0.1%) (Fleischhacker, 1992). Other side-effects include 299 
hypersalivation, metabolic syndrome, reduced seizure threshold, constipation, tachycardia, 300 
myocarditis, cardiomyopathy, pulmonary embolism and extrapyramidal symptoms among 301 
others (Farooq and Taylor, 2011; Mistry and Osborn, 2011). Additionally, clozapine’s 302 
sedative and anticholinergic effects may cause worsening of cognition in patients with ID 303 
(Sajatovic et al. 1994). However, unlike many other antipsychotics, clozapine is not 304 
associated with inducing hyperprolactinaemia as a side effect   (Mortimer, 2011). Less 305 
commonly occurring side-effects include acute pancreatitis (Martin, 1992), neuroleptic 306 
malignant syndrome (DasGupta and Young, 1991), hepatitis, interstitial nephritis, paralytic 307 
ileus and priapism (Ziegler and Behar, 1992). Recently published NICE guidelines (NICE, 308 
2009) acknowledge the paucity of studies in relation to treatment and management of 309 
personality disorder (Lindsay et al., 2007). The guidelines recommend specialist input from 310 
ID services for assessment, diagnosis and management when dual diagnosis of BPD and ID is 311 
suspected. 312 
  313 
Conclusion 314 
It is likely that clozapine prescription brought about a reduction in impulsivity, a core 315 
hallmark of BPD, increasing ‘thinking time’ in each of the 5 cases, enabling the use of 316 
alternative coping strategies rather than maladaptive responses when faced with real or 317 
imagined stressors. Each of the 5 people described developed a more positive outlook to life, 318 
had an increased self-esteem and self-confidence. They also showed significant 319 
improvements in their ability to meaningfully interact and engage with support workers and 320 
professionals in the ID team over a sustained period and increased use of adaptive and 321 
socially acceptable coping strategies over time. As with any other treatment, the potential 322 
adverse effects with clozapine needs to be regularly monitored and weighed up carefully 323 
against the benefits derived.  324 
 325 
Recent literature recommends earlier introduction of clozapine in treatment resistant 326 
schizophrenia (Farooq and Taylor, 2011; Mistry and Osborn, 2011).  Similarly, our clinical 327 
experience of working with patients who have a diagnosis of personality disorder and 328 
complex life threatening symptoms also shows that clozapine would clinically be a highly 329 
valuable alternative to other pharmacological approaches, especially when psycho-social 330 
strategiesalone could not manage the risks adequately. Use of clozapine under robust 331 
monitoring (though unlicensed in the management of personality disorders), as an adjunct to 332 
non-pharmacological approaches, will in our opinion facilitate engagement and compliance 333 
and ensure the safety and quality of life of the patients with severe personality disorders in 334 
the community.  335 
  336 
 337 
 338 
 339 
 340 
 341 
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